COVID-19大流行期间风险适应性头颈癌放疗实践建议:ASTRO-ESTRO共识声明
ASTRO与ESTRO针对COVID-19大流行期间头颈癌放疗资源受限与风险增高的情况,采用改良快速Delphi流程组织国际专家组制定实践建议。专家组评估早期(风险缓解)与晚期(放疗资源严重减少)两种大流行情景,针对5例头颈癌病例形成治疗推荐,并在治疗优先级、感染期间放疗延迟或中断、剂量分割与化疗使用、手术病例管理及门诊随访调整等方面达成一致或强烈一致。
要点
- 制定两种大流行情景下的头颈癌放疗实践推荐:早期风险缓解与晚期资源严重减少。
- 对治疗优先级、SARS-CoV-2感染期间是否延迟或中断放疗等达成一致或强烈一致。
- 共识覆盖放疗剂量分割方案、化疗使用、手术病例管理及门诊与支持治疗调整。
核心结论
- 该紧急实践建议旨在资源受限与健康风险增高的大流行期间确保高质量头颈癌治疗持续进行,以挽救生命并获得症状获益。
研究设计与样本
- ASTRO、ESTRO及部分亚太国家国际专家组完成改良快速Delphi流程,每轮在线调查开放24小时且下一轮在前一轮结束后24小时内启动。
- 采用从RAND方法外推的强烈一致(≥80%)与一致(≥66%)切点,评估早期与晚期两种大流行情景,针对5例头颈癌病例制定治疗推荐。
- 受邀31人中29人接受(94%),经替换后30人完成全部3次调查(应答率100%)。
主要发现
- 专家组在治疗优先级、并发SARS-CoV-2感染时是否延迟开始或中断放疗、各情景下放疗剂量分割与化疗使用、手术室关闭时手术病例管理、门诊预约与支持治疗调整等方面达成一致或强烈一致。
关键数值与推荐
- 强烈一致定义为≥80%,一致定义为≥66%,切点从RAND方法外推。
- 评估早期(风险缓解)与晚期(放疗资源严重减少)两种大流行情景,针对5例头颈癌病例制定推荐。
- 30名专家完成全部3次调查,应答率100%。
临床怎么用
- 在COVID-19大流行资源受限期间,可参照该共识对头颈癌放疗进行风险适应性优先级排序与治疗调整。
- 对并发SARS-CoV-2感染的患者,可参照共识决定是否延迟开始或中断放疗。
- 可根据早期或晚期大流行情景选择相应的放疗剂量分割方案与化疗使用策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. METHODS AND MATERIALS: A panel of international experts from ASTRO, ESTRO, and select Asia-Pacific countries completed a modified rapid Delphi process. Topics and questions were presented to the group, and subsequent questions were developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (≥80%) and agreement (≥66%) were extrapolated from the RAND methodology. Two pandemic scenarios, early (risk mitigation) and late (severely reduced radiation therapy resources), were evaluated. The panel developed treatment recommendations for 5 HNC cases. RESULTS: In total, 29 of 31 of those invited (94%) accepted, and after a replacement 30 of 30 completed all 3 surveys (100% response rate). There was agreement or strong agreement across a number of practice areas, including treatment prioritization, whether to delay initiation or interrupt radiation therapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care. CONCLUSIONS: This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit.
引用
- Thomson DJ, Palma D, Guckenberger M, et al. Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. Int J Radiat Oncol Biol Phys. 2020. PMID: 32302681. doi:10.1016/j.ijrobp.2020.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。